DNMT1 and cancer: Currently, two DNMT inhibitors 5-Azacytidine (AZA, vidaza) and its deoxyribose analog, 5-aza-2′-deoxycytidine (decitabine), are approved by Food and Drug Administration (FDA) as anti-cancer agents.